# BE6A LUNG-01 (NCT06012435)

> A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06012435
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Seagen, a wholly owned subsidiary of Pfizer
- Conditions: Carcinoma, Non-Small-Cell Lung
- Interventions: sigvotatug vedotin; docetaxel
- Enrollment: 762
- Primary outcome: Overall survival (OS) between the experimental arm (sigvotatug vedotin) and control arm (docetaxel)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=be6a-lung-01-nct06012435